Herbal injection, immunotherapy, and chemo before lung cancer surgery
Part of Cancer, Immune system & allergy, Lungs & breathing clinical trials.
This trial tests a combination of an injectable herbal medicine (Shenqi Fuzheng), an immunotherapy drug (PD-1 inhibitor), and chemotherapy before surgery for early-stage lung cancer. The goal is to see if this approach can shrink tumors and improve the immune system's response, potentially leading to better outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with resectable non-small cell lung cancer (NSCLC) that is stage IB (with a tumor 4 cm or larger), IIA, or IIIA.
- You have not had immunotherapy or platinum-based chemotherapy in the past.
- Your tumor does not have EGFR mutations or ALK rearrangements.
- You are in generally good health, with a performance status of 0 or 1 (able to do daily activities).
- You do not have a history of interstitial lung disease, autoimmune diseases requiring treatment, or organ transplantation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of an immunotherapy drug (QL1706) plus chemotherapy given before and after surgery for people with certain stages of non-small cell lung cancer (NSCLC). The goal is to see if this approach helps shrink the tumor and improves outcomes.
This trial tests a combination of medicines given before surgery and immunotherapy after surgery for resectable non-small cell lung cancer (NSCLC). It aims to shrink the tumor before the operation and reduce the risk of cancer coming back after surgery.
This trial tests a new combination of radiation, two immunotherapy drugs, and chemotherapy given before surgery for non-small-cell lung cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for patients with stage II-III disease that can be removed with surgery.
This trial compares giving immunotherapy before and after surgery versus only after surgery for people with early-stage but advanced lung cancer. It aims to see which timing might better help keep the cancer from coming back.
This trial tests a new approach for people with certain advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes in the chest but might still be removed. It combines a short course of high-precision radiation, immunotherapy (sintilimab), and standard chemotherapy before surgery to see if it can improve outcomes.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
Hear when a new Tear Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.